Erlotinib is marketed by OSI Pharma in US and by Roche in non US areas.
Pre grant opposition of product patent 537/DEL/1996
Erlotinib infringement case:
Erlotinib product patent is granted in India [Patent No:IN196774, Application No:537/DEL/1996] equivalent to US 5747498. Cipla announced launch of generic version of Tarceva [Erlotinib]. Roche sued Cipla in Delhi High court for infringement of product patent ['774] and to grant injunction to market cipla product.
Injunction was denied to Roche
Pre grant oppositions of Polymorph related patents
OSI has filed to two patent applications, which are equivalent to US 6900221
IN/PCT/2002/507/DEL [Cipla Vs OSI] granted as ??
IN/PCT/2002/497/DEL [Cipla Vs OSI] granted as ??
No comments:
Post a Comment